IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Holdings Lifted by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. boosted its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 82.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 16,249 shares of the company’s stock after buying an additional 7,356 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in IDEAYA Biosciences were worth $515,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in IDEAYA Biosciences by 17.0% during the fourth quarter. Vanguard Group Inc. now owns 3,475,772 shares of the company’s stock valued at $123,668,000 after buying an additional 504,275 shares in the last quarter. Entropy Technologies LP acquired a new position in shares of IDEAYA Biosciences in the 1st quarter valued at $679,000. Jennison Associates LLC acquired a new position in shares of IDEAYA Biosciences in the 1st quarter valued at $11,244,000. Nisa Investment Advisors LLC boosted its position in shares of IDEAYA Biosciences by 38.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,340 shares of the company’s stock valued at $117,000 after purchasing an additional 927 shares during the period. Finally, Swiss National Bank boosted its position in shares of IDEAYA Biosciences by 30.9% in the 1st quarter. Swiss National Bank now owns 111,400 shares of the company’s stock valued at $4,888,000 after purchasing an additional 26,300 shares during the period. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Performance

Shares of IDYA stock opened at $29.86 on Wednesday. The stock’s 50 day simple moving average is $33.78 and its 200 day simple moving average is $37.20. IDEAYA Biosciences, Inc. has a twelve month low of $25.22 and a twelve month high of $47.74. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -14.86 and a beta of 0.82.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.14). During the same quarter last year, the company earned ($0.50) earnings per share. On average, analysts forecast that IDEAYA Biosciences, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IDYA has been the subject of a number of recent analyst reports. Cantor Fitzgerald initiated coverage on IDEAYA Biosciences in a research report on Tuesday, October 15th. They issued an “overweight” rating for the company. Lifesci Capital raised IDEAYA Biosciences to a “strong-buy” rating in a research note on Monday, July 29th. BTIG Research increased their price objective on IDEAYA Biosciences from $55.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Finally, JPMorgan Chase & Co. cut their price target on IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Fourteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IDEAYA Biosciences has an average rating of “Buy” and a consensus price target of $55.45.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.